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Abstract
Vasomotor symptoms (VMS) experienced during menopause can negatively impact a
woman’s quality of life, productivity, sleep, and mood. Systemic hormone therapy (HT) is the
most effective treatment for moderate to severe VMS, however safety concerns raised by the
2002 Women’s Health Initiative (WHI) trial have led to a decrease in overall HT use and a
growing demand for custom-compounded bioidentical HT. Misconceptions regarding the
superior safety and efficacy of custom-compounded hormones and lack of clinician expertise in
menopause management contribute to ongoing uncertainty and low uptake of United States
(U.S.) Food and Drug Administration (FDA) approved bioidentical HT products. This literature
review evaluates current evidence regarding the safety and efficacy of bioidentical HT to provide
clinical guidance for patient education and prescribing practices. Twenty-eight articles published
from 2015-2020 were included in the final review, consisting of systematic reviews, metaanalyses, randomized control trials (RCTs), cohort studies, case control studies, and literature
reviews. Current evidence suggests that FDA approved bioidentical hormones are more effective
than placebo and equally effective compared to synthetic hormones when used to treat
menopausal VMS. Safety of bioidentical HT was evaluated based on its associated risk of breast
cancer, endometrial cancer, venous thromboembolism (VTE), stroke, and cardiovascular disease
(CVD). Findings suggest that safety profiles depend on the duration of therapy, route, regimen,
and individual factors but bioidentical HT is generally safe for women without contraindications
if low to medium doses are used for five years or less.
Keywords: menopause, vasomotor symptoms, hot flashes, night sweats, efficacy,
bioidentical hormone therapy, estradiol, progesterone, safety, breast cancer, endometrial cancer,
stroke, venous thromboembolism, cardiovascular disease
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Safety and Efficacy of Bioidentical Hormone Therapy in Menopause: A Literature Review
Menopause is the cessation of menstruation due to the natural decline in ovarian function
or surgical removal of the ovaries and can be clinically diagnosed 12 months following the final
menstrual period (FMP) (Stuenkel et al., 2015). Menopausal VMS including hot flashes and
night sweats “are associated with a sudden sensation of heat in the face, neck, and chest and
persist for several minutes or less. Vasomotor symptoms may include flushing, chills, anxiety,
sleep disruption, and palpitations” (Kauntiz & Manson, 2015, p. 2). The pathophysiology of
VMS is not completely understood; however, it likely involves altered thermoregulation and
release of neuroendocrine, cytokine, and stress hormones due to fluctuating sex hormone levels
(Kaunitz & Manson, 2015).
The average age of natural menopause in the U.S. is 51 and menopausal transition, or
perimenopause, may begin as early as age 40 (Kaunitz & Manson, 2015). VMS increase
throughout perimenopause and peak approximately 1 year after the FMP (Kaunitz & Manson,
2015). Up to 80% of women experience VMS during the menopausal transition (Gold et al.,
2006; Woods & Mitchell, 2005) and at least 50% report moderate to severe symptoms that
interfere with quality of life (Freeman et al., 2014). A U.S. observational study showed that
“frequent VMS lasted more than 7 years during the menopausal transition for more than half of
the women and persisted for 4.5 years after the FMP” (Avis et al., 2015, p. 531). Frequent and
severe VMS also occur following oophorectomy due to the sudden shift in estrogen and
progesterone levels (Kaunitz & Manson, 2015).
VMS can negatively impact a woman’s occupational, physical, emotional, and sexual
quality of life and often prompt women in the U.S. to seek medical treatment (Nicholson et al.,
2001; Utian, 2005; Williams et al., 2007). “Untreated menopausal symptoms are also associated
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with higher health care costs and loss of work productivity” (Manson & Kaunitz, 2016, p. 803).
Mild VMS can often be managed with lifestyle modifications such as weight reduction, smoking
cessation, wearing layered clothing, and maintaining a cool environment (Goodman et al., 2011).
Pharmaceutical treatment options for moderate to severe VMS include systemic HT, selective
serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs),
gabapentin, pregabalin, or clonidine patches (Goodman et al., 2011; North American Menopause
Society, 2012; Stuenkel et al., 2015). For those without contraindications, estrogen therapy (ET)
“with or without a progestogen is the most effective treatment of menopause-related vasomotor
symptoms and their potential consequences, such as diminished sleep quality, irritability,
difficulty concentrating, and subsequently reduced quality of life (QOL)” (North American
Menopause Society, 2012, p. 3).
The dose, route, and regimen of HT can be individualized based on patient preferences,
risk factors, hysterectomy status, symptomology, and goals of treatment. While systemic
estrogen only therapy can be prescribed for women who have undergone hysterectomy, a
progestogen must be added to provide endometrial protection for those with an intact uterus
(Goodman et al., 2011; North American Menopause Society, 2012; Stuenkel et al., 2015).
Estrogen is available in oral, transdermal (TD), or vaginal formulations and concurrent
progestogens may be given orally or vaginally in a combined continuous (CC), sequential
continuous (SC), or alternate day regimen. With CC estrogen progestogen therapy (EPT), both
hormones are taken daily and with SC EPT the progestogen is given for 12-14 days each month
(Yang et al., 2017). The lowest effective dose of HT should be given to control VMS and
minimize adverse effects such breast tenderness, vaginal bleeding, bloating, and headaches.
Current guidelines suggest that HT is safe for women “within 10 years of menopause who are at
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low risk of cardiovascular disease and breast cancer” (Ward & Deneris, 2018, p. 169). Extended
use may be warranted in some situations after informed, shared decision making, and
discontinuation of HT should not be based on age alone (Santoro et al., 2019; Ward & Deneris,
2018).
The use of systemic HT dramatically decreased among U.S. women after the initial
findings of the Women’s Health Initiative (WHI) were published in 2002 (Manson & Kaunitz,
2016). Although the WHI was designed to evaluate the risks and benefits of long-term synthetic
hormone therapy for postmenopausal women (average age 63 at therapy initiation), it is now
being used to guide treatment decisions for women in their 40s and 50s who have distressing
VMS (Manson & Kaunitz, 2016). While there are several FDA approved bioidentical HT options
and sufficient research to support their use, they remain underutilized in the U.S. (Manson &
Kaunitz, 2016). This is in part due to the misconception that compounded hormones are safer
and more ‘natural’ than pharmaceutical bioidentical HT. The purpose of this literature review is
to synthesize the current evidence regarding the following clinical question: In perimenopausal
and postmenopausal women, what is the safety and efficacy of bioidentical hormone therapy in
treating vasomotor symptoms?
Background
Initial findings from the WHI trial (Rossouw et al., 2002) reported that the combination
of conjugated equine estrogen (CEE) with medroxyprogesterone (MPA) (both synthetic
hormones) increased the risk of coronary heart disease (CHD), stroke, breast cancer, and VTE in
postmenopausal women. This resulted in a 32% reduction in HT prescriptions and a greater than
60% reduction in CEE/MPA prescriptions in the U.S. despite further analysis suggesting that the
WHI findings may not apply to peri- and newly menopausal women (Majumdar et al., 2004).
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Since that time many women have opted for custom-compounded bioidentical HT “on the
assumption that it would be safer than other forms of HT” (Gaudard et al., 2016, p. 3).
Bioidentical hormones from compounding pharmacies are often referred to as ‘natural
hormones’ and have been marketed as having “fewer risks and side effects, and greater efficacy
than commercially available HT preparations” (Stanczyk et al., 2021, p. 38). One million to 2.5
million U.S. women ages 40 and older currently use compounded HT, accounting for 28% to
68% of HT prescriptions (Pinkerton & Santoro, 2015). Most women who use compounded
bioidentical HT report that it was recommended by their physician and are not aware that these
products lack FDA-approval (Pinkerton & Santoro, 2015). Professional organizations including
the American College of Obstetricians and Gynecologists, American Society for Reproductive
Medicine, North American Menopause Society, Endocrine Society, American Association of
Clinical Endocrinologists, and American College of Endocrinology recommend against the use
of compounded HT “due to concerns regarding reliability of dosage, purity, lack of evidence
regarding superior effectiveness over FDA-approved hormonal formulations and lack of FDA
oversight” (Santoro et al., 2019, p. 30). In 2020, the National Academies of Sciences,
Engineering, and Medicine (NASEM) conducted an extensive study of compounded bioidentical
HT and recommend prescribers restrict its use to two circumstances: “patients with allergies to
specific components of FDA-approved hormone therapy, or patients who require a dosage form
not currently available as an FDA-approved drug product” (p. 195).
“The term ‘bioidentical hormone’ generally refers to sex steroid hormones, usually an
estrogen, an androgen or progesterone, that has the same chemical and molecular structure [and
physiological effect] as the endogenous hormone produced in the body” (Stanczyk et al., 2021, p.
38). Bioidentical hormones are often derived from natural plant substances; however, all
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bioidentical hormones, whether they are custom-compounded or pharmaceutical formulations,
require some degree of chemical synthesis in the lab (Stanczyk et al., 2021). Synthetic hormone
is a term used to describe formulations that differ in chemical structure and physiologic effect
compared to endogenous hormones (Stanczyk et al., 2021). It is implied that all synthetic
hormones are ‘manufactured’ in the lab, which is not the case. Conjugated equine estrogen
(CEE) is derived from female horse urine and does not require any chemical synthesis, however
it is considered a synthetic estrogen because it does not share the same chemical and physiologic
properties as human estrogen (Stanczyk et al., 2021).
The following terms will be used in this literature review to differentiate between
bioidentical and synthetic formulations. Progestogen encompasses both synthetic progestin (P)
and bioidentical progesterone (P4). Bioidentical estrogen encompasses estrone (E1), estradiol
(E2), estriol (E3), and estetrol (E4). E2 and E3 are widely used in Europe and Asia but only E2
products are FDA approved for use in the U.S. (Moskowitz, 2006). Custom compounded HT
formulations may include any combination of P4, E1, E2, or E3 (Stanczyk et al., 2021).
FDA approved 17-beta estradiol is available in the U.S. in oral, transdermal, and vaginal
formulations; under generic and brand names such as Estrace, Alora patch, and Vagifem
(Santoro et al., 2019). Products combining oral or transdermal 17-beta estradiol with a synthetic
progestin are also available (i.e. Activella, Climara Pro) (Santoro et al., 2019). Not all estradiol
products are bioidentical which can create confusion for patients and clinicians; for example
estradiol acetate is considered bioidentical whereas ethinyl estradiol is synthetic. Bioidentical P4
is available in an oral micronized formulation prepared in peanut oil (Prometrium), vaginal
preparation (Prochieve 4%), or in a combined oral capsule with 17-beta estradiol (Bijuva)
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(Santoro et al., 2019). MPA, norethindrone acetate (NETA), and levonorgestrel (LNG), are
synthetic progestins that are completely man-made (Stanczyk et al., 2021).
Numerous FDA approved formulations of 17-beta estradiol and progesterone are
available for U.S. women seeking bioidentical HT for the treatment of menopausal VMS.
Clinicians caring for menopausal women often report having received inadequate training and
many do not realize that FDA approved bioidentical hormones are available (Kling et al., 2019;
Files et al., 2016; Manson & Kaunitz, 2016). This leads to reluctance in prescribing HT and
ineffective counseling of women who might benefit from bioidentical therapies.
Method
Data abstraction process
A literature search was completed from 10/24/20 to 1/17/21 using CINAHL, Academic
Search Premier, PubMed, and Cochrane Database of Systematic Reviews. Table 1 in the attached
appendix includes details on search restrictions, dates included, and general subjects covered by
each database.
Study Selection
Search terms comprised of “bioidentical hormone replacement therapy”, “bioidentical
hormones", “menopause”, “perimenopause”, “vasomotor symptoms”, “estradiol”, “CEE”,
“conjugated equine estradiol”, “progesterone”, “REPLENISH trial”, “safety”, “risk”, and
“cancer”. Search limits included publications from 2015-2020, full text availability, English
language, and peer reviewed academic journals. Articles were initially reviewed and eliminated
if the title and abstract did not address the clinical question. Duplications were also eliminated. A
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bibliographic review identified five additional articles that were ultimately included. See Table 2
in the appendix for search term combinations and the number of unique hits from each database.
Search Strategies
Table 3 in the appendix includes all articles that were reviewed for inclusion or exclusion
criteria. Articles were included if they (1) included perimenopausal and/or postmenopausal
women, (2) evaluated the efficacy of oral or TD bioidentical hormones in treating VMS, (3)
evaluated the safety of bioidentical hormones regarding VTE, stroke, cardiovascular, breast
cancer, or endometrial cancer risk, (4) compared bioidentical HT to non-users, placebo, and/or
synthetic HT, or (5) compared various formulations, doses, regimens, or routes of bioidentical
HT. Articles were excluded if they (1) evaluated the safety or efficacy of low-dose vaginal
estrogen, (2) measured menopausal outcomes of genitourinary symptoms, sleep quality, or
mood, (3) were expert reviews or commentary on original studies, (4) were available in abstract
only, (5) or did not differentiate between bioidentical and synthetic hormones when evaluating
the efficacy or risk of HT.
Literature Review Process
Twenty-eight articles met inclusion criteria and consisted of systematic reviews, metaanalyses, RCTs, case control studies, cohort studies, and literature reviews. The systematic
reviews and meta-analyses included large, well-designed RCTs, observational, and populationbased case control and cohort studies. Retrospective observational studies often relied on
insurance claims to determine HT use, type of HT, co-morbid conditions, and participant
demographics. This introduced a potential for error in International Classification of Diseases,
Tenth Revision (ICD-10) coding, and did not provide specific dosing, duration, regimen, or

10

adherence data. Safety studies were more likely to be observational in nature compared to
efficacy studies due to the longer duration required to evaluate for risk and the associated cost of
long-term controlled studies.
Methodological Assessment
The twenty-eight articles included in the literature review were categorized into three
groups: bioidentical HT efficacy, safety, or both. The safety articles were further categorized into
five groups: breast cancer, endometrial cancer, VTE, stroke, or cardiovascular disease.
Synthesizing the data was challenging due to heterogeneity of the studies and numerous factors
impacting safety outcomes. The search terms and databases most likely to yield results were
utilized for this literature review, however it is possible that some relevant literature was missed.
By limiting search dates to the past five years, older studies with valuable findings may have
been excluded, but the systematic reviews and meta-analyses included in this review encompass
individual studies dating back over 20 years. This literature review therefore represents the
current state of evidence regarding the safety and efficacy of bioidentical HT for the treatment of
menopausal VMS.
Literature Review
Efficacy of Oral Estradiol
Gaudard et al. (2016) conducted a systematic review and meta-analysis of 23 RCTs
comparing the efficacy of 17-beta estradiol to CEE or placebo and found low to moderate quality
evidence suggesting that bioidentical estradiol is more effective than placebo in treating
moderate to severe VMS. Efficacy was dose dependent but higher doses also resulted in more
adverse effects such headache, vaginal bleeding, breast tenderness, and skin reactions. There was
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no evidence to suggest a difference in efficacy between estradiol and CEE. The authors were
unable to make specific treatment recommendations due to individual study limitations including
risk of bias due to poor reporting of methods, imprecision, and lack of analyzable data.
The REPLENISH trial (Lobo et al., 2018) investigated the efficacy of TX-001HR, a
combined oral E2/P4 capsule, given daily at various doses to treat moderate to severe VMS.
Frequency and severity of VMS significantly decreased from baseline with the 1mg/100mg and
0.5mg/100mg doses compared to placebo at week 4 and week 12. Additional analyses of the
REPLENISH trial demonstrated a clinically meaningful reduction in hot flashes (Constantine et
al., 2019) and more VMS-free days (Kaunitz et al., 2020) in the treatment groups versus placebo.
Coelingh Bennink et al. (2016) conducted a small, partly randomized open-label,
multiple-rising-dose study (N=49) comparing the efficacy of 2mg oral estradiol valerate (E2V)
and 2mg and 10mg oral E4 in treating postmenopausal VMS. Oral E4 is a weak estrogen steroid
hormone produced by the fetal liver and is only present at detectable levels during human
pregnancy (Coelingh Bennink et al., 2016). Neither of these products are FDA approved for
menopausal HT however oral E2V is widely used in Europe. Participants with an intact uterus
were randomized to receive 2mg of unopposed E2V or 2mg of unopposed E4 on days 1-28.
During the dose escalation phase of the study, women who experienced 35 or more hot flashes
per week at baseline were then given 10mg of E4 on days 29-56. Hot flashes and sweating were
recorded in a daily diary by all participants on days 1-56. The authors concluded that all
treatment groups were equally effective at decreasing VMS (see Table 4).
Efficacy of Transdermal Estradiol
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Transdermal estradiol can be administered as a gel, patch, or spray to treat moderate to
severe VMS in menopause. Derzko et al. (2016) performed a systematic review and network
meta-analysis to indirectly compare the efficacy of several estradiol gels and doses. The authors
concluded that Divigel 0.25 mg, Divigel 0.5 mg, and Estrogel 0.75 mg showed similar efficacy
and were all statistically superior to Estrogel 1.5 mg (see Table 4). Divigel 1.0 mg provided the
best efficacy profile but was also associated with a higher risk of adverse effects including
postmenopausal bleeding, headache, breast pain, infection, nausea, rash, and vaginitis. The
discontinuation rate with Divigel 1.0 mg was only 5% which suggests that the benefits of
improved efficacy may outweigh the risk of adverse effects for some women.
A systematic review and network meta-analysis by Kovács et al. (2016) indirectly
compared the efficacy of estradiol metered dose transdermal spray (MDTS) and estradiol patches
given at doses ranging from 14-50mcg. Both formulations resulted in similar reductions in hot
flash frequency over a 12-week period with a dose dependent response. All but the 14mcg
estradiol patch resulted in statistically significant improvements in VMS when compared to
placebo. These findings suggest that estradiol MDTS and estradiol patches produce comparable
reductions in VMS when given at similar doses.
Efficacy of Low-Dose Estradiol
The Kronos Early Estrogen Prevention Study (KEEPS) (Harman et al., 2005) was a
multicenter RCT that compared the effects of low-dose oral CEE (0.45mg), TD estradiol
(50mcg), and a placebo on cardiovascular outcomes in recently menopausal women (average 22
months post FMP). A secondary analysis of the KEEPS trial by Santoro et al. (2017) showed that
both treatment arms experienced a significant and similar reduction in moderate to severe VMS
when compared to the placebo group. Subgroup analyses also showed that symptom relief was
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not significantly modified by body mass index (BMI), race, or ethnicity (Santoro et al., 2017).
The authors concluded that “recently menopausal women had similar and substantial reductions
in hot flashes and night sweats with lower than conventional doses of oral or TD estrogen. These
reductions were sustained over 4 years” (Santoro et al., 2017, p. 3).
Malik et al. (2016) conducted a randomized single blind, four arm, parallel assignment
study (N=200) comparing the efficacy of low-dose oral E2V, oral CEE, and a placebo in
reducing postmenopausal VMS. Self-reported severity and frequency of hot flashes were used to
calculate a hot flash score (average hot flash severity x daily frequency). Follow up at 24 weeks
revealed a significant reduction in mean hot flash score for both E2V and CEE (91.9% and
89.2% reduction respectively). The authors concluded that low doses of oral E2V and CEE were
equally effective in treating VMS over 24 weeks.
A systematic review of nine double blind placebo-controlled trials (N=3069) by Corbelli
et al. (2015) found that low-dose TD estradiol (less than 50mcg) was more effective than placebo
at reducing the frequency of moderate to severe hot flashes. A dose dependent response was
observed with estradiol doses ranging from 0.003mg-0.045mg (see Table 4).
Efficacy of Progesterone Only Therapy
Progesterone only therapy can be used to treat VMS in women who have
contraindications or a personal preference to avoid estrogen. Systematic reviews by Dolitsky et
al. (2021) and Prior (2018) included a limited number of smaller RCTs that showed mixed
therapeutic efficacy of standalone progesterone. One RCT (N=133) concluded that 300mg of
daily oral micronized P4 significantly decreased VMS scores in the treatment group compared to
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placebo (Hitchcock & Prior, 2012). There is insufficient evidence to support the use of low-dose
TD P4 for menopausal VMS (Prior, 2018).
Safety of Bioidentical HT: Breast Cancer
The E3N-Epic study by Fournier et al. (2005) was a prospective study (N=98,997)
conducted in France that followed menopausal women over an eight-year period and calculated
the hazard ratio (HR), or likelihood of developing breast cancer after receiving HT. A hazard
ratio of 1.0 indicates that the HT intervention had no impact on the outcome (breast cancer)
whereas HR greater than 1.0 represents an increased risk and HR less than 1.0 represents a
decreased risk (Melnyk & Fineout-Overholt, 2015). Fournier et al. (2005) concluded that breast
cancer risk was lowest for those receiving bioidentical EPT (HR 0.9; 95% CI 0.7, 1.2) and
bioidentical ET (HR 1.1; 95% CI 0.8, 1.6), and higher for those receiving bioidentical estrogen
with synthetic progestin (HR 1.4; 95% CI 1.2, 1.7). These findings suggest than regimens
containing a synthetic progestin pose a greater risk of breast cancer than bioidentical
formulations.
A retrospective study by Zeng et al. (2018) compared breast cancer incidence among
12,404 women who received various types of HT after age 50 and 27,642 non-HT users. The
authors concluded that ET with CEE or estradiol both resulted in a significant reduction in breast
cancer risk (see Table 4). CEE plus MPA also significantly reduced breast cancer risk which
conflicts with previous WHI findings (Rossouw et al., 2002). A non-significant increase in breast
cancer risk occurred with estradiol plus progesterone (see Table 4). In a direct comparison of the
two combination therapies, the authors concluded that CEE plus MPA is superior to estradiol
plus progesterone from a breast cancer safety standpoint.
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A systematic review and meta-analysis by Yang et al. (2017) evaluated breast cancer risk
associated with unopposed estradiol and estradiol plus progestogen including subgroup analysis
based on progestogen type, duration of exposure, and regimen. All 14 studies used E2V or 17beta estradiol with a synthetic progestin or micronized P4, however doses and routes of
administration were not specified. Breast cancer risk was increased in the EPT group, but
subgroup analysis showed that the risk varied based on progestogen type. A statistically
significant increase in breast cancer risk was noted with EPT containing synthetic progestins
(MPA, NETA, and LNG) but there was no increased risk with EPT containing oral micronized
P4 or dydrogesterone (see Table 4). Estradiol-only therapy showed no increased risk of breast
cancer (see Table 4). Bioidentical estradiol combined with a progestogen increased breast cancer
risk when used for longer than five years; however, the authors were unable to perform subgroup
analysis based on progestogen type due to small sample sizes. Bioidentical estradiol given with
CC or SC progestogen increased breast cancer risk with more significant risk associated with a
CC regimen.
Stute et al. (2018) conducted a systematic review evaluating breast cancer incidence
associated with EPT containing micronized P4. Estrogen (synthetic or bioidentical) paired with
oral or vaginal P4 did not increase breast cancer risk if used for five years or less. However,
limited evidence suggests that breast cancer risk increases after five years. Only two studies
(Espié et al., 2007; Fournier et al., 2005) measured breast cancer incidence after five years of HT
use; both were prospective cohort studies and lacked detailed reporting of compliance, dosage,
and route of P4.
A systematic review of three observational studies (N=86,881) compared breast cancer
risk based on progestogen type (Asi et al., 2016). Meta-analysis conducted on two of the cohort
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studies showed that EPT with P4 may be associated with lower breast cancer risk compared to
EPT with synthetic progestin (RR 0.67; 95% CI 0.55-0.81) however the included studies had a
moderate risk of bias (Asi et al., 2016). A population-based case control study showed no
increased risk of breast cancer associated with estrogen plus progesterone, (OR 0.80; 95% CI
0.44–1.43) and a non-significant increase with estrogen plus progestin, (OR 1.57; 95% CI 0.992.49) (Cordina-Duverger et al., 2013). Findings suggest that P4 may be safer than progestins,
however study limitations include the risk of bias and confidence intervals crossing the null
hypothesis (1).
Safety of Bioidentical HT: Endometrial Cancer
Mirkin et al. (2020) conducted a secondary analysis of the REPLENISH trial (Lobo et al.,
2018) and concluded that all doses of the combined E2/P4 capsule provided adequate
endometrial protection for up to one year. Coelingh Bennink et al. (2016) measured endometrial
thickness over an eight-week period of daily unopposed E4 use. The 10mg dose resulted in
endometrial hyperplasia but the 2mg dose did not. Findings suggest that higher doses of E4
require endometrial protection with a progestogen whereas the 2mg dose may not.
Systematic reviews by Sjögren et al. (2016) and Tempfer et al. (2020) evaluated
endometrial cancer risk based on type of progestogen and regimen used. Both reviews included
two large European cohort studies (Allen et al., 2010; Fournier et al., 2014) and concluded that
micronized P4 increases endometrial cancer risk (see Table 4). Subgroup analysis of the E3N
study (Fournier et al., 2014) found that short term use (five years or less) of P4 may be safe;
however, endometrial cancer risk increased after five years of use. A large systematic review by
Stute et al. (2016) included 40 studies utilizing EPT with various forms, regimens, and doses of
P4 and concluded:
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(1) oral micronized progesterone provides endometrial protection if applied sequentially
for 12–14 days/month at 200 mg/day for up to 5 years; (2) vaginal micronized
progesterone may provide endometrial protection if applied sequentially for 10
days/month at 4% (45 mg/day) or every other day at 100 mg/day for up to 3–5 years (offlabel use); (3) transdermal micronized progesterone does not provide endometrial
protection. (p. 327)
Safety of Bioidentical HT: Cardiovascular Disease, VTE, and Stroke
Simon et al. (2016) were the first to provide a direct comparison of oral estrogen and TD
estradiol. In this large matched cohort study (N=5102) conducted over a 10-year period, women
receiving TD estradiol were found to have a significantly lower incidence of CVD events
compared with those receiving oral ET (see Table 4). Subgroup analysis revealed statistically
significant reductions of VTE overall, DVT, and heart failure; and non-statistically significant
reductions of pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, and
angina in the TD estradiol group compared to the oral ET group. Unfortunately, the type of oral
estrogen was not specified in this study, so it is unclear if patients received synthetic or
bioidentical formulations.
A nested case control study in France (Canonico et al., 2016) identified 3,144 women
who were hospitalized for their first episode of ischemic stroke (IS) and 12,158 matched
controls. Insurance claims data were obtained to identify current users of oral or TD 17-beta
estradiol (with or without a progestogen) and odds ratios were adjusted based on medications and
diagnostic codes for diabetes, hypertension, and dyslipidemia. Compared to nonusers, oral E2
was found to increase IS risk in a dose dependent manner whereas no increased risk occurred
with TD E2 (see Table 4). The authors also investigated IS risk based on progestogen type and
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found that TD E2 plus P4 did not increase IS risk whereas TD E2 plus synthetic norpregnane
derivatives did (see Table 4).
A meta-analysis of seven well-designed population-based observation studies evaluated
VTE risk based on progestogen type and found that “in transdermal estrogen users, there was no
change in VTE risk in women using micronized progesterone (RR 0.93, 95% CI 0.65–1.33),
whereas norpregnane derivatives were associated with increased VTE risk (RR 2.42, 95% CI
1.84–3.18)” (Scarabin, 2018, p. 341).
Lobo et al. (2019) completed a secondary analysis of the REPLENISH trial (Lobo et al.,
2018) and found that continuous oral E2/P4 had no significant effect on cardioembolic markers
including lipids, coagulation factors, or blood glucose. The non-significant effect on triglyceride
levels seen with the E2/P4 capsule were similar to findings by Harman et al. (2005) using TD E2
and cyclic P4. Although the study by Lobo et al. (2019) lacked statistical power to determine
cardiovascular outcomes such as stroke, VTE, and coronary heart disease, the incidence of
cardiovascular events in those receiving the E2/P4 capsule was comparable to expected rates in
the general population.
A single center RCT by Hodis et al. (2016) explored the relationship between timing of
HT initiation and progression of subclinical atherosclerosis, measured by carotid-artery intimamedia thickness (CIMT). Healthy post-menopausal women (N=643) were randomized to receive
oral 17-beta estradiol (with SC vaginal progesterone if their uterus was intact) or a placebo. For
women in early menopause (less than 6 years since FMP), the rate of CIMT progression was
significantly lower in the estradiol group than in the placebo group. Women in late menopause
(10 years or more since FMP) did not demonstrate any difference in CIMT progression as
compared to the control group (see Table 4). Estradiol had no significant impact on clinical
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atherosclerosis in either group; however, cardiac computed tomography was not performed at
baseline and not all participants followed up after study completion.
Limited evidence suggests that P4 does not diminish the cardiovascular benefits of
estrogen and is likely safer than progestins; however, existing RCTs have not measured coronary
heart disease directly (Eden, 2017). Asi et al. (2016) attempted to conduct a systematic review
and meta-analysis of studies comparing cardiovascular events with EPT containing P4 versus
progestin. The authors were unable to find any studies that met inclusion criteria and suggested
that further research be conducted in this area. When given at 300mg daily for 12 weeks to treat
VMS, oral P4 caused no change in weight, waist circumference, blood pressure, fasting glucose,
lipids, C-reactive protein, or D-dimer compared to placebo (Prior, 2018).
Quality Indicators
This literature review included systematic reviews, meta-analyses, RCTs, and prospective
and retrospective observational studies with varied sample sizes, risk of bias, reporting detail,
and heterogeneity which made it difficult to interpret findings and formulate specific
recommendations for clinical practice. Most of the efficacy studies were RCTs whereas safety
studies were more often observational in nature. The observational studies allowed for longer
duration of follow up and larger sample sizes but were limited by the lack of control groups.
Multiple studies also provided limited details regarding HT doses, routes, and formulations.
Many studies were well-designed with adequate sample sizes to power statistical significance,
yet the confidence interval occasionally crossed 1 (e.g. 95% CI 0.9-1.1) which implies no
difference between arms of the study (Melnyk & Fineout-Overholt, 2015). Many studies reported
a low risk of bias or explained methods used to exclude studies with higher bias.
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Variables such as hormone formulation, dose, regimen, route, application method,
participant age, timing of HT initiation, severity of symptoms, and health status impact the
outcomes of interest and complicate the evaluation and synthesis of research findings. This
review included studies conducted in the U.S. and Europe, therefore some of the HT
formulations are not FDA approved or available in the U.S. Dropout rates were reported in some
studies and although significant at times, re-analysis often confirmed that results were not
impacted by attrition. Studies reported severity and/or frequency of VMS using a validated tool
or self-report method. Validated tools increase the accuracy of VMS reporting but also increase
the burden on participants and may lead to higher attrition rates. VMS diaries were maintained
before and during the treatment period which promoted accurate recall of symptoms. The
REPLENISH trial was funded and supported by TherapeuticsMD, manufacturer of the now FDA
approved Bijuva, however bias was minimized due to its double blinded, randomized design.
Gaps in Literature
Overall there was a lack of diversity in study subjects with most participants being white,
non-Hispanic, healthy, and well educated. Additional research is needed to evaluate the safety
and efficacy of bioidentical HT in a more ethnically and socially diverse population and in
women with underlying health conditions. There is also a needed for well-designed RCTs
comparing different doses, regimens, and routes of bioidentical hormones. It is difficult to
determine long-term safety outcomes with RCTs due to their relatively shorter duration
compared to observational studies, however observational studies lack controls and are more
prone to bias. Research regarding the safety of low-dose TD estradiol is lacking particularly in
the areas of cardiovascular disease and breast cancer risk. Additional research involving
perimenopausal women is also needed as most studies included postmenopausal women only.
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Discussion
Efficacy
Evidence suggests that various doses of TD and oral estradiol, including lower than
standard TD doses, are more effective than placebo in reducing menopausal VMS (Gaudard et
al., 2016; Kovács et al., 2016; Lobo et al., 2018; Santoro et al., 2017) and equally effective
compared to synthetic estrogen/CEE (Corbelli et al., 2015; Malik et al., 2016; Santoro et al.,
2017). The efficacy of low-dose TD E2 (50mcg/day) was consistent across ethnic and racial
groups and was not impacted by BMI (Santoro et al., 2017). TD and oral estradiol reduce VMS
in a dose dependent manner however higher doses often result in unwanted adverse effects,
which may lead to discontinuation (Corbelli et al., 2015; Derzko et al., 2016; Gaudard et al.,
2016). When given in equivalent doses, estradiol TD patches and MDTS were equally effective
although MDTS may produce fewer localized skin reactions resulting in better tolerability and
adherence (Kovács et al., 2016).
The E2/P4 combined daily capsule studied in the REPLENISH trial resulted in
statistically significant (Lobo et al., 2018) and clinically meaningful (Constantine et al., 2019)
reductions in the frequency and severity of VMS and more symptom free days (Kaunitz et al.,
2020) compared to a placebo. The 1mg/100mg dose has since been approved by the FDA, under
the brand name Bijuva, as the first combined bioidentical EPT for the treatment of menopausal
VMS. Once daily dosing with a single combined capsule may improve patient adherence and
control of symptoms. Unlike oral micronized progesterone, Bijuva does not contain peanut oil
and can be safely used by those with a peanut allergy.
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E4 may be a safe and effective bioidentical HT option for treating menopausal VMS
(Coelingh Bennink et al., 2016) but is not currently approved for use in the U.S. or Europe.
Additional E4 research is needed with larger sample sizes and longer duration of treatment.
Evidence is lacking to support widespread use of progesterone-only therapy to treat VMS;
however, it may be an option for women who are unable or unwilling to use systemic estrogen.
Barriers to using progesterone-only treatment include lack of provider awareness and patient
discontinuation due to headache and vaginal bleeding (Dolitsky et al., 2021; Prior, 2018).
Breast Cancer
Research suggests that EPT containing P4 does not increase breast cancer risk and is
safer than EPT with synthetic progestins (Asi et al., 2016; Fournier et al., 2005; Yang et al.,
2017; Zeng et al., 2018). Estradiol plus P4 resulted in a non-significant increase (Zeng et al.,
2018) or no change in breast cancer risk (Fournier et al., 2005), and estradiol plus synthetic
progestin increased breast cancer risk (Yang et al., 2017). ET (estradiol or CEE) was found to
decrease or have no significant effect on breast cancer risk (Fournier et al., 2005; Zeng et al.,
2018). EPT with synthetic or bioidentical estrogen plus oral or vaginal P4 did not increase breast
cancer risk if used for five years or less; limited evidence suggests that this risk may increase
after five years (Stute et al., 2018). No conclusions can be drawn regarding breast cancer risk
associated with SC and CC regimens containing P4 due to inadequate sample sizes (Stute et al.,
2018). Most studies evaluating breast cancer risk did not specify HT doses, routes, or regimens
however current evidence suggests that ET (synthetic or bioidentical) and EPT with oral or
vaginal P4 do not increase the risk of breast cancer if used for five years or less.
Endometrial Cancer
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Women with an intact uterus should receive EPT due to the increased risk of endometrial
cancer associated with unopposed estrogen (Goodman et al., 2011). Oral P4 provides adequate
endometrial protection when given continuously at 100mg (Eden, 2017; Lobo et al., 2018) or
sequentially at 200mg (Eden, 2017; Stute et al., 2016). Vaginal P4 can be administered every
other day at 100mg or sequentially at 4% (45 mg/day) for 10 days per month (Eden, 2017; Stute
et al., 2016). Transdermal P4 does not provide adequate endometrial protection (Stute et al.,
2016). Short term use (five years or less) of oral P4 for endometrial protection did not
statistically increase the incidence of endometrial cancer (Sjögren et al., 2016; Tempfer et al.,
2020). Continuous oral P4 may provide greater endometrial protection than cyclic use however
neither regimen resulted in elevated endometrial cancer risk after five years (Tempfer et al.,
2020). Since there is no clinical benefit to giving oral P4 sequentially, continuous use is
recommended to minimize endometrial cancer risk (Zeng et al., 2018).
Cardiovascular, VTE, and Stroke
Oral E2 was found to increase VTE and IS risk in a dose dependent manner however no
increased risk occurred with TD E2 or TD E2 plus P4 (Canonico et al., 2016; Scarabin et al.,
2018; Simon et al., 2016). These findings suggest that “TD estrogens alone or combined with
micronized progesterone may be the best option to improve the risk benefit ratio of HT use and
may represent the safest option with respect to both VTE and stroke risk” (Canonico et al, 2016,
p. 1740).
Research on bioidentical HT and CVD is lacking. None of the included studies measured
CVD directly and instead used surrogate markers such as lipids, vascular function, weight, waist
circumference, blood pressure, and fasting glucose. While these markers represent CVD risk
factors, they do not always predict future development of CVD. Findings from the REPLENISH
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trial showed no significant effect on cardioembolic markers with all doses of the E2/P4 capsule
(Lobo et al., 2019). Standalone P4 used to treat VMS may also have a neutral effect on surrogate
markers for CVD (Prior, 2018). One RCT (Hodis et al., 2016) found that estradiol may slow the
progression of subclinical atherosclerosis if initiated within six years of menopause, however the
authors acknowledged that CIMT is not the only predictor of CVD.
Implications for Future Practice
Recommendations for Clinical Practice
Clinicians have a responsibility to their patients “to ensure that their decision making is
based on evidence-based health information and is supported by techniques of shared decision
making” (NASEM, 2020, p. 196). Based on current evidence, clinicians can confidently
recommend FDA approved bioidentical hormones to women who are seeking an alternative to
conventional synthetic hormones, have no contraindications to HT, and experience moderate to
severe VMS despite lifestyle modifications. If bioidentical HT is prescribed, clinicians should
initiate oral or TD estradiol at a low-dose (0.003mg-0.05mg) and titrate to optimally balance
symptom control with adverse effects. The timing of HT discontinuation should be
individualized and never based on age alone, although discontinuation within five years may
pose a lower risk of breast and endometrial cancer depending on the regimen. CC, SC, or
alternate day vaginal P4 provides adequate endometrial protection in women with an intact
uterus. There are a variety of FDA approved formulations available to meet the needs of most
women. Custom-compounded hormones should generally be avoided except for rare cases where
a woman does not tolerate FDA approved therapies due to allergies or the recommended dose is
not commercially available (NASEM, 2020).
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Recommendations for Research
Additional well-designed RCTs and observational studies evaluating various routes,
doses, and regimens of FDA approved bioidentical hormones are needed to determine which are
safest and most effective in treating VMS. These studies should include a broad and diverse
demographic sample (ethnicity, race, health status, education, etc.), longer duration of follow-up,
adequate sample sizes, and direct comparison of different bioidentical hormones. Current gaps in
the literature include direct comparisons of TD E2 preparations, RCTs evaluating the efficacy of
oral P4 in treating VMS, and safety studies evaluating the impact of bioidentical HT on CVD.
Additional research involving perimenopausal women is also needed as most studies included
postmenopausal women only. Well-designed RCTs are needed to better understand the potential
health benefits and risks, scope, and financial costs associated with commonly prescribed
compounded bioidentical HT preparations.
Recommendations for Education
Physicians and advance practice providers often receive inadequate training in
menopause management which leads to uncertainty and confusion regarding the efficacy and
safety of HT, ineffective counseling of women seeking care, and overall reluctance to prescribe
HT for those who may benefit (Manson & Kaunitz, 2016). Primary care and OB-GYN residency
programs and advanced practice provider programs should include menopause management as a
core competency and provide clinical opportunities to further develop knowledge and skills.
Advanced practice provider fellowship programs are one option for newly graduated family
nurse practitioners and physician assistants to gain women’s health experience. Ongoing
continuing education should be offered to primary care and women’s health providers to ensure
that evidence-based recommendations are being implemented in practice.
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Recommendations for Policy
Collaboration between the FDA, state medical and pharmacy boards, and other
stakeholders is needed to increase state and federal regulatory oversight of custom compounded
bioidentical HT to ensure that adequate quality standards are maintained and documented
(NASEM, 2020). Oversight should also include processes to improve data collection and
surveillance of adverse events associated with compounded products. Compounding pharmacies
are not currently required to include comprehensive product labels or standardized package
inserts which:
provide opportunities for ambiguous instructions for use, incomplete listing of active and
inactive ingredients, or an omission of potential contraindications, all of which creates the
potential for patients and prescribers to be inadequately informed about possible safety
concerns related to the use of these medications. (NASEM, 2020, p. 6)
Additional labeling and packaging requirements including black box warnings, non-FDA
approved status, indications and guidance for use, dosage, ingredients, expiration date,
contraindications, side effects, and instructions on how to report adverse events would enhance
patient awareness and safe use of compounded HT (NASEM, 2020).
Conclusion
FDA approved bioidentical hormones provide a safe and effective treatment option for
peri- and postmenopausal women with moderate to severe VMS who are seeking a bioidentical
option and have no contraindications to HT. Bioidentical HT is available in a variety of
formulations, doses, routes, and regimens, is more effective than placebo, and equally effective
compared to synthetic hormones. Research included in this literature review suggests that
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estradiol and progesterone are generally safe to use from a breast cancer, endometrial cancer,
VTE, and stroke perspective although safety depends on the route, dose, regimen, duration of
treatment, and individual risk factors. Estradiol with or without P4 poses no additional risk of
breast cancer if used for five years or less. TD estradiol with or without P4 is safer than oral
estrogen or EPT with progestin when considering VTE risk. Oral E2 was found to increase
ischemic stroke risk in a dose dependent manner however no increased risk occurred with TD E2
or TD E2 plus P4. Additional research is needed to evaluate CVD risk although research with
surrogate markers are reassuring. “Midwives and nurse practitioners are ideally suited to provide
evidence‐based care for menopause‐related symptoms as professionals committed to assessing
each woman based on her overall risks and personal preferences” (Ward & Deneris, 2018, p.
168). This includes counseling women on the risks and benefits of FDA approved bioidentical
HT, recommending its use when clinically appropriate, and offering an individualized treatment
plan to effectively reduce VMS and improve the quality of life for women during the menopause
transition and beyond.
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https://doi.org/10.1080/13697137.2016.1221919
Lieberman, A.& Curtis, L. (2017). In defense of progesterone: A review of the
literature. Alternative Therapies in Health and Medicine, 23(6), 24-32.
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Pickar, J. H., Graham, S., Bernick, B., & Mirkin, S. A. (2018). 17β-estradiolprogesterone oral capsule for vasomotor symptoms in postmenopausal women:
A randomized controlled trial. Obstetrics & Gynecology, 132(1), 161-170.
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use and the risk for cardiovascular mortality. Human Reproduction, 31, 804–
809. https://doi.org/10.1093/humrep/dew014
Mirkin, S., Goldstein, S. R., Archer, D. F., Pickar, J. H., Graham, S., &
Bernick, B. (2020). Endometrial safety and bleeding profile of a 17βestradiol/progesterone oral softgel capsule (TX-001HR). Menopause, 27(4),
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Mirkin, S., Graham, S., Revicki, D. A., Bender, R. H., Bernick, B., &
Constantine, G. D. (2019). Relationship between vasomotor symptom
improvements and quality of life and sleep outcomes in menopausal women
treated with oral, combined 17β-estradiol/progesterone. Menopause, 26(6),
637-642. https://doi.org/10.1097/GME.0000000000001294

Excluded

Evaluated vaginal estradiol prescribed for vulvovaginitis and
associated CV risk

Included

Evaluated the effect of a single-capsule 17β-estradiol/progesterone
(E2/P4), TX-001HR, on endometrial safety
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Evaluated the impact of TX-001HR (17b-estradiol–progesterone) on
quality of life and sleep.

days in the REPLENISH trial. Menopause, 27(12), 1-6.
https://doi.org/10.1097/GME.0000000000001615

Included
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Prior, J. C. (2015). Progesterone or progestin as menopausal ovarian hormone
therapy: Recent physiology-based clinical evidence. Current Opinion in
Endocrinology, Diabetes and Obesity, 22(6), 495-501.
https://doi.org/10.1097/MED.0000000000000205

Excluded

Focused on physiology of progestogens and E3N study (already
included in literature review).

Prior, J. C. (2018). Progesterone for treatment of symptomatic menopausal
women. Climacteric, 21(4), 358–365.
https://doi.org/10.1080/13697137.2018.1472567

Included

Review of evidence obtained from randomized control trials,
population and observational data regarding safety and effectiveness
of oral micronized progesterone in treating vasomotor symptoms

Santoro, N., Allshouse, A., Neal-Perry, G., Pal, L., Lobo, R. A., Naftolin, F.,
Black, D. M., Brinton, E. A., Budoff, M. J., Cedars, M. I., Dowling, N. M.,
Dunn, M., Gleason, C. E., Hodis, H. N., Isaac, B., Magnani, M., Manson, J. E.,
Miller, V. M., Taylor, H. S., Wharton, W., Wolff, E., Zepeda, V., Harman, S.
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https://doi.org/10.1097/GME.0000000000000756.
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Updated meta-analysis evaluating risk of venous thromboembolism
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Simon, J. A., Laliberté, F., Duh, M. S., Pilon, D., Kahler, K. H., Nyirady, J.,
Davis, P. J., & Lefebvre, P. (2016). Venous thromboembolism and
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Sjögren, L. L., Mørch, L. S., & Løkkegaard, E. (2016). Hormone replacement
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progesterone on breast cancer risk: A systematic review. Climacteric, 21(2),
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Systematic review of studies evaluating breast cancer risk associated
with estrogen plus micronized progesterone
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Pregnanes 1.00 (95% CI,
0.60–1.67);
Nortestosterone 1.26 (95%
CI, 0.62–2.58)

Claims data from
French national
health insurance
system

Further research is needed to
evaluate CV risk of EPT w/
MP4 and P.
TD estrogens alone or
combined with MP4 may be
the best option to improve the
benefit/risk ratio of HT use
and may represent the safest
option with respect to IS risk.
RCTs are needed to confirm
these results

↑risk Norpregnanes 2.25
(95% CI, 1.05–4.81).
Coelingh Bennink, H.,
Verhoeven, C., Zimmerman,
Y., Visser, M., Foidart, J. M.,
& Gemzell-Danielsson, K.
(2016). Clinical effects of the
fetal estrogen estetrol in a
multiple-rising-dose study in

Evaluate the
safety and
efficacy of
estetrol (E4) in
treating PM
VMS

N=49
PM ♀
age <70,
≥6 months
since LMP,
BMI 18-30

PROL
MRDS
Level 3

DV=Episodes per
day of hot flashes
and sweating; selfrecorded in diary
on day 1-56 (all
doses)

randomized

with intact
uterus:
unopposed

E4 2mg or
E2V 2mg
x 28 days

VMS at day 28 follow up:
All groups: ↓ mean number
of hot flashes/sweating
Hot flashes (episodes/day):
E2V 2mg: 11.5  6.5; E4

2mg and 10 mg E4 dose and
2mg E2V equally effective in
reducing number of hot
flashes and sweating
Endometrial proliferation
occurred with E4 10 mg but
not 2mg indicating that
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postmenopausal women.
Maturitas, 91, 93–100.
https://doi.org/10.1016/j.matu
ritas.2016.06.017
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Size (n)
/Setting(s)

Design/
Level of
Eviden
ce
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Instruments

DV=Endometrial
thickness:
ultrasound at
baseline, day 14,
28, and 56.
endometrial
biopsy at baseline
and day 28 if
thickness ↑ ≥50%

Netherlands

Interventi
on

nonrandomized

Findings

Implications

2mg: 9  5.6; E4 10mg:
8.4  5

endometrial protection with
progestogen is necessary for
10mg dose but may not be
needed for 2mg dose.

doseescalation
day 29-56

Sweating (episodes/day):
E2V 2mg: 3.5  2.3; E4
2mg: 4.4  2.4; E4 10mg:
2.6  1.4

E4 10mg
if intact
uterus &
≥35 hot
flashes per
week

VMS at day 56 follow up:
Hot flashes (episodes/day):
E2V 2mg 1.8; E4 2mg 1.8;
E4 10mg 1.8

unopposed

Sweating (episodes/day):
E2V 2mg 0; E4 2mg 1.6;
E4 10mg 0.9
Endometrial thickness:
E4 2mg: stable

Further research of E4 in
treating menopausal VMS is
needed with a minimum
treatment time of 12 weeks to
further evaluate safety and
efficacy.
Small phase I and II studies
cannot be generalized to
practice without further
research.

E2V 2mg & E4 10mg: ↑
Constantine, G. D., Revicki,
D. A., Kagan, R., Simon, J.
A., Graham, S., Bernick, B.,
& Mirkin, S. (2019).
Evaluation of clinical
meaningfulness of estrogen
plus progesterone oral capsule
(TX-001HR) on moderate to
severe vasomotor symptoms.
Menopause, 26(5), 513-519.
https://doi.org/10.1097/GME.
0000000000001261

Determine the
clinical
meaningfulness
of TX-001HR in
reducing
moderate to
severe VMS

n=726

RCT

PM ♀

Level 2

See Lobo
et al.
(2018)

DV= CID and
minimal CID in
VMS severity at
weeks 4 and 12
Clinical Global
Impression scale
and MenopauseSpecific Quality
of Life
(MENQOL)
questionnaire

oncedaily, oral
E2/P4
(mg/mg)
of 1/100,
0.5/100,
0.5/50,
0.25/50,
or placebo

Significantly more women
had a clinically meaningful
improvement in the
number of hot flashes in all
treatment groups versus
placebo

TX-001HR provided clinically
meaningful improvements in
menopausal VMS.
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Corbelli, J., Shaikh, N.,
Wessel, C., & Hess, R.
(2015). Low-dose transdermal
estradiol for vasomotor
symptoms: A systematic
review. Menopause, 22(1),
114–121.
https://doi.org/10.1097/gme.0
000000000000258

Evaluate
effectiveness of
low dose TD
estrogen in PM
♀ with
moderate to
severe hot
flashes

N=3069

SR

PM ♀
women ≥7
hot flashes
per day
and/or ≥50
hot flashes
per week

Level 1

DV=mean daily
number of hot
flashes

Low dose
TD E (less
than 0.05
mg 17βestradiol)

All doses of TD E more
effective than placebo

Strong evidence to suggest
that low-dose TD E is more
effective than placebo in
reducing the frequency of
moderate to severe hot flashes.

Mode of
TD
delivery
varied
(patch,
gel, spray)

Estrogen dose 0.03750.045mg: ↓9.36

Derzko, C., Sergerie, M.,
Siliman, G., Alberton, M., &
Thorlund, K. (2016).
Comparative efficacy and
safety of estradiol transdermal
preparations for the treatment
of vasomotor symptoms in
postmenopausal women: An
indirect comparison metaanalysis. Menopause, 23(3),
294–303.
https://doi.org/10.1097/GME.
0000000000000552

Compare
efficacy of
different TD
E2 preparations
for the treatment
of VMS in PM
♀

Dolitsky, S. N., Cordeiro
Mitchell, C. N., Sheehan
Stadler, S., & Segars, J. H.
(2020). Efficacy of progestinonly treatment for the
management of menopausal

Assess if
progestogen
only treatment
is effective for
treating VMS

N=1517
Mean age
50.5-55.0
Mean BMI
25.8 to
27.9

9 DBPC
RCTs

SR and
network
MA

DV: frequency
and severity of hot
flashes

Level 1
5 RCTs

Followed
for 12-13
weeks
Divigel
0.25mg
and
0.5mg,
Estrogel
0.75mg
and 1.5mg

North
America
and Europe

N=601

SR
Level 1

DV=severity and
frequency of hot
flashes; VMS
score

TD MP4
5-60 mg
Oral MPA
10-20mg

Mean daily # of hot
flashes:

Estrogen dose 0.0200.029mg: ↓7.91

Dose dependent relationship
observed

Estrogen dose 0.0030.0125 mg: ↓7.07
Placebo groups: ↓5.07.
Divigel 0.25 mg, Divigel
0.5 mg, and Estrogel 0.75
showed similar efficacy
and all were statistically
superior to Estrogel 1.5
mg.
Best efficacy profile
Divigel 1.0mg (mean
difference 3.91 hot
flushes/week vs placebo)

Mixed efficacy results
Largest study using
transdermal progesterone:
no improvement (n = 230).

Best efficacy profile resulted
from Divigel 1.0mg, but also
associated with higher risk of
AEs compared to other
formulations. Despite AEs,
only 5% of participants
discontinued treatment with
Divigel 1.0 mg. Further
research is needed with head
to head comparison of
transdermal estradiol
preparations.
Monotherapy with
progestogens can be used to
treat VMS in women with
contraindications to estrogens.
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symptoms: A systematic
review. Menopause, 28(2), 18.
https://doi.org/10.1097/GME.
0000000000001676

associated with
menopause.

Eden, J. (2017). The
endometrial and breast safety
of menopausal hormone
therapy containing micronised
progesterone: A short review.
Australian & New Zealand
Journal of Obstetrics &
Gynaecology, 57(1), 12–15.
https://doi.org/10.1111/ajo.12
583

Review of
literature
evaluating
endometrial,
breast, and CV
safety of
estrogen+MP4

Pop (N)/
Sample
Size (n)
/Setting(s)

N/A

Design/
Level of
Eviden
ce

Narrativ
e review

Variables/
Instruments

Interventi
on

Findings

Implications

Greene
Climacteric Scale,
Menopause
Specific Quality
of Life
Questionnaire,
weekly diary

Duration:
21 days to
12 months
(median
12 weeks)

Side effects (headaches,
vaginal bleeding, etc.)
significant in 5 of 7
studies; treatment
discontinuation 6%-21%

Current research with mixed
results and additional RCTs
with larger sample sizes are
needed to determine efficacy,
safety, and tolerability of
progesterone only for VMS.

IV=MP4; various
forms and doses

N/A

MP4 (oral CC or SC and
alternate day vaginal) is
effective in preventing
endometrial
hyperplasia/EC
CV risk: MP4 likely safer
than P

Oral MP4 200mg cyclic or
100mg daily and vaginal MP4
100mg every other day
adequately protects the
endometrium when given with
low to medium dosage
estrogen to manage
menopause symptoms.

CEE and oral E2 ↑ risk of
VTE/stroke but TD E2 (gel
or patch) does not. MPA
significantly ↑risk of VTE.
MP4 “could be safe”
regarding VTE

Transdermal E2 + oral or
vaginal MP4 is most likely a
safe and effective option for
women with moderate to
severe VMS seeking
bioidentical HT.

BC: HT regimens with
MP4 have significantly
↓BC risk compared to P

Need large RCTs comparing
vaginal vs. oral MP4

DV=endometrial
hyperplasia & EC
Transvaginal
ultrasound
Endometrial
biopsy
CV markers:
lipids, metabolic
syndrome, and
vascular function

Need RCTs evaluating MP4
with heart disease as measured
outcome.
Gaudard A., Silva de Souza,
S., Puga, M., Marjoribanks, J.,
da Silva, E., & Torloni, M. R.

Determine the
effectiveness of
bioidentical

N=5779
20/23
studies

SR &
MA

IV=ET
DV=Frequency
and intensity of

Unoppose
d 17 betaestradiol;

low to moderate quality
evidence that E2 in various

E2 is likely more effective
than placebo in treating
moderate to severe VMS. No
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(2016). Bioidentical hormones
for women with vasomotor
symptoms. Cochrane
Database of Systematic
Reviews, 8(CD010407), 1103.
https://doi.org/10.1002/14651
858.CD010407.pub2

estrogen
compared to
placebo or
synthetic
estrogen for
relief of
menopausal
VMS

included
only ♀with
moderate
to severe
hot flashes.

Level 1

hot flushes and
night sweats

various
doses and
forms
(patch,
gel, oral,
intranasal,
emulsion)
vs. CEE
or placebo

forms and doses is more
effective than placebo

clear difference in efficacy
between E2 and CEE. Dose
dependent response.

Hodis, H. N., Mack, W. J.,
Henderson, V. W., Shoupe,
D., Budoff, M. J., HwangLevine, J., Li, Y., Feng, M.,
Dustin, L., Kono, N.,
Stanczyk, F. Z., Selzer, R. H.,
& Azen, S. P. (2016).
Vascular effects of early
versus late postmenopausal
treatment with estradiol. New
England Journal of Medicine,
374(13), 1221-1231.
https://doi.org/10.1056/NEJM
oa1505241

Determine if
CV effects of
PM HT (E2)
vary with timing
of initiation

N=643
healthy PM
♀ with or
without
uterus

Kaunitz, A. M., Bitner, D.,
Constantine, G. D., Bernick,
B., Graham, S., & Mirkin, S.
(2020). 17βestradiol/progesterone in a

Determine the
number of
VMS-free days
with E2/P4
versus placebo

23
RCTs

RCT
Level 2

Symptom intensity
measured on a 0100 visual
analogue scale

IV=Early
menopause <6
years or late ≥10
years
DV=Rate of
change in CIMT;
at baseline then
every 6 months
with high
resolution B-mode
ultrasound

Single
center U.S.

oral 17b
estradiol
+/sequential
vaginal P4
gel vs.
placebo

RCT
Level 2

DV=change in
moderate to severe
VMS, moderate to

Not all studies reported
analyzable data; no MA
Mean CIMT (mm/year) at
median of 5 years:
Early menopause group:
E2 w/ or w/o P4: ↑0.0044
Placebo ↑0.0078
Late menopause group:
E2 w/ or w/o P4 ↑0.0100
Placebo 0.0088
Cardiac CT (all groups;
mean 6 years follow up):
coronary artery calcium,
total stenosis, and plaque
did not differ significantly

Coronary
atherosclerosis:
cardiac CT upon
completion of
therapy (no
baseline obtained,
not all received)
n=726

no evidence showing
difference in effectiveness
between bioidentical HT
and CEE

oncedaily, oral
E2/P4

In all treatment groups:

Cannot make specific
treatment recommendations
due to study limitations: risk
of bias/poor reporting of
methods, imprecision, and
lack of analyzable data.
Oral E2 associated with less
progression of subclinical
atherosclerosis (measured by
CIMT) than placebo if
initiated within 6 years of
menopause. CIMT
progression was not impacted
in late menopause group.
There may be a CV benefit to
starting estradiol within 6
years of menopause.
E2 had no significant impact
on atherosclerosis regardless
of timing of initiation,
however no baseline cardiac
CT was obtained and there
was a smaller sample size
receiving post-completion CT.
Women treated with E2/P4
had a greater response to
treatment with more VMS-free
days than placebo.
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single, oral, softgel capsule
(TX-001HR) significantly
increased the number of
vasomotor symptom-free days
in the REPLENISH
trial. Menopause, 27(12), 1-6.
https://doi.org/10.1097/GME.
0000000000001615

in REPLENISH
trial.

See Lobo
et al.
(2018)

Kovács, G., Zelei, T., &
Vokó, Z. (2016). Comparison
of efficacy and local
tolerability of estradiol
metered-dose transdermal
spray to estradiol patch in a
network metaanalysis. Climacteric, 19(5),
488–495.
https://doi.org/10.1080/13697
137.2016.1221919
Lobo R. A., Archer, D. F.,
Kagan, R., Kaunitz, A. M.,
Constantine, G. D., Pickar, J.
H., Graham, S., Bernick, B.,
& Mirkin, S. A. (2018). 17βestradiol-progesterone oral
capsule for vasomotor
symptoms in postmenopausal
women: A randomized
controlled trial. Obstetrics &
Gynecology, 132(1), 161-170.
https://doi.org/10.1097/AOG.
0000000000002645

Compare
efficacy of E2
MDTS vs. E2
patch in treating
VMS

Design/
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Eviden
ce

Variables/
Instruments

Interventi
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Findings

severe VMS-free
days at 12 weeks

See Lobo
et al. 2018

Significant ↑ in 50% and
75% responders at weeks 4
& 12

VMS diary

Implications

Significant ↑ in VMS-free
days at week 12
43-56% of ♀ without
severe hot flushes at week
12 versus 26% for placebo

N=?
(unable to
access
appendix)

SR and
network
MA for
indirect
compari
son

DV= relative
change (%) in
number of hot
flashes between
baseline and week
12

E2
MDTS,
E2 patch,
or placebo

DV=change in
frequency and
severity of
moderate to severe
VMS at weeks 4
and 12

oncedaily, oral
E2/P4
(mg/mg)
of 1/100,
0.5/100,
0.5/50,
0.25/50,
or placebo
for up to
52 weeks

Level 1

Dose
range 1450mcg

8 RCTs
Evaluate the
efficacy of a
single-capsule
17b-estradiol–
progesterone
(TX-001HR) for
treating
menopausal
moderate-tosevere VMS

n=726

RCT

PM ♀ w/
intact
uterus

Level 2

mean age
55; mean
BMI 27;
White 67%
AA 31%

All treatment groups
except 14mcg/day patch
had a significant ↓ in
number of hot flashes
compared to placebo

When applied in similar doses,
E2 MDTS and E2 patches
have similar efficacy in
treating menopausal VMS.

No significant difference in
efficacy between E2
MDTS and E2 patch; dose
dependent response
Frequency and severity of
VMS significantly ↓ from
baseline with E2/P4
1mg/100mg and 0.5mg/
100mg compared with
placebo at week 4 and
week 12

TX-001HR is the first
continuous combined oral
E2/P4 capsule to treat
moderate-to-severe PM VMS
and provides an effective and
convenient option for women
seeking bioidentical HT.
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Lobo, R. A., Kaunitz, A. M.,
Santoro, N., Bernick, B.,
Graham, S., & Mirkin, S.
(2019). Metabolic and
cardiovascular effects of TX001HR in menopausal women
with vasomotor symptoms.
Climacteric, 22(6), 610-616.
https://doi.org/10.1080/13697
137.2019.1640197doi:10.108
0/13697137.2019.1640197
Malik, S., Pannu, D., Prateek,
S., Sinha, R., & Gaikwad, H.
(2016). Comparison of the
symptomatic response in
Indian menopausal women
with different estrogen
preparations for the treatment
of menopausal symptoms: A
randomized controlled
trial. Archives of Gynecology
and Obstetrics, 293(6), 13251333.
https://doi.org/10.1007/s0040
4-016-4034-9

Evaluate the
effects of single
capsule E2/P4
(TX-001HR) on
cardiometabolic
markers and
outcomes when
used to treat
VMS

N=1835

RCT

DV=Lipid,
coagulation
factors, and blood
glucose drawn at
baseline, 6, 9, and
12 months

See Lobo
et al. 2018

No clinically significant
effects on lipids,
coagulation factors, or
blood glucose between
treatment groups and
comparing treatment
groups with placebo.

Neutral effects on TGs

Determine VMS
response
comparing
bioidentical
estradiol,
synthetic
estrogen,
isoflavones, and
placebo

N=200

Mirkin, S., Goldstein, S. R.,
Archer, D. F., Pickar, J. H.,
Graham, S., & Bernick, B.
(2020). Endometrial safety
and bleeding profile of a 17βestradiol/progesterone oral
softgel capsule (TX001HR). Menopause, 27(4),

Evaluate
endometrial
safety of single
capsule E2/P4
(TX-001HR)
when used to
treat VMS

Level 2

CV events

PM ♀ with
surgical,
natural, or
premature
menopause
up to age
70

RCT
single
blind, 4
arm,
parallel
assignm
ent
Level 2

BMI <36

DV= Severity and
frequency of hot
flashes
Hot flash score
(average hot flash
severity x daily
frequency)
calculated at
baseline, 4, 12, 24,
and 28 weeks.

New Delhi,
India

n=1255

RCT
Level 2

DV=endometrial
hyperplasia
endometrial
biopsy at baseline
and 52 weeks

CV adverse events (1
DVT, 3 CVD)
oral E2V
0.5-1mg,
oral CEE
0.3-0.625
mg,
phytoestrogens
60mg or
placebo x
24 weeks
CC MP4
200mg
given if
uterus
intact
See Lobo
et al. 2018

E2V and CEE ↓severity
and frequency of hot
flashes.
Mean hot flash score at 24week follow up:

Lacked statistical power to
determine CV outcomes
(stroke, VTE, CHD).
Incidence of CV events in
treatment group similar to
expected rates in general
population.
Low doses of both CEE and
E2V were equally effective for
management of VMS when
administered over 24 weeks.

E2V: ↓91.9%
CEE: ↓89.2%
Isoflavones: ↓60.42%
Placebo: ↓47.9%

Incidence of endometrial
hyperplasia ≤0.36%
regardless of dose after one
year of use

All doses of TX-001HR
provide adequate endometrial
protection up to one year.
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410-417.
https://doi.org/10.1097/GME.
0000000000001480
Prior, J. C. (2018).
Progesterone for treatment of
symptomatic menopausal
women. Climacteric, 21(4),
358–365.
https://doi.org/10.1080/13697
137.2018.1472567

Evaluate the
efficacy and
safety of MP4
only therapy for
the treatment of
menopausal
VMS

N=varies

SR

PM ♀

Level 1

DV=frequency
and intensity of
hot flashes; VMS
score calculated
from daily log

TD MP4,
oral MP4,
w/ or w/o
ET

RCT (N=133): statistically
significant ↓VMS score at
12 weeks (55% decrease
w/ oral MP4 vs. 29% w/
placebo); no serious AEs

Oral MP4 is likely safe and
effective in treating
menopausal VMS either alone
or in combination with
estrogen.

RCT (N=24) no change in
weight, BP, lipids, waist
circumference, fasting
glucose, CRP, or D-dimer
at 12 weeks compared to
placebo

Insufficient evidence to
support transdermal P4 in
treating VMS

Compare the
efficacy of low
dose oral CEE
vs. TD E2 plus
MP$ or placebo
in treating VMS
in early MP ♀

N=727

RCT

♀ age 42–
58, ≥6
months but
<36
months
from last
menses

Level 2

Lower than conventional
doses of oral CEE and TD E2
provide significant relief of
menopausal VMS up to 48
months. Both options are
equally effective therefore TD
E2 is a viable option for
women seeking bioidentical
HT for the treatment of VMS.

Santoro, N., Allshouse, A.,
Neal-Perry, G., Pal, L., Lobo,
R. A., Naftolin, F., Black, D.
M., Brinton, E. A., Budoff, M.
J., Cedars, M. I., Dowling, N.
M., Dunn, M., Gleason, C. E.,
Hodis, H. N., Isaac, B.,
Magnani, M., Manson, J. E.,
Miller, V. M., Taylor, H. S.,
Wharton, W., Wolff, E.,
Zepeda, V., Harman, S. M.
(2017). Longitudinal changes
in menopausal symptoms
comparing women
randomized to low-dose oral
conjugated estrogens or
transdermal estradiol plus
micronized progesterone
versus placebo: The Kronos
Early Estrogen Prevention

DV=CV makers

9 sites
across the
U.S.

DV= reduction in
moderate-severe
hot flashes and
night sweats

oral CEE
0.45 mg
or TD E2
50mcg

Moderate to severe hot
flashes and night sweats:
Baseline: 44% and 35%
respectively

Hot flashes and
night sweats selfreported at
baseline and at 6,
12, 24, 36, and 48
months.

both given
w/ oral
MP4
200mg x
12 days
per month
or placebo

At 6-month follow up:
Significant ↓ in all
treatment groups.
Hot flashes: placebo
28.3%; TD E2 7.4%; oral
CEE 4.2%
Night sweats: placebo
19%; TD E2 5.3%; oral
CEE 4.7%
No significant differences
between CEE and TD E2
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Symptom relief was not
significantly modified by
BMI or race/ethnicity.
Evaluate VTE
risk based on
route of
estrogen
administration,
hormone
regimen, and
progestogen
type

N=26,471
PM ♀ with
VTE

Evaluate risk of
VTE and CVD
complications
for menopausal
♀ using TD
estradiol vs. oral
ET

N=5102

Evaluate
endometrial
safety of PM
HT use based
on regimen and
type of
progestogen

N=902 PM
♀ w/ EC

MA
Level 1
4 CCS,
3 CS

DV=First episode
idiopathic VTE
(DVT or PE),
VTE recurrence,
or secondary VTE
Measured with
objective imaging

♀ ≥ 50

Uncontr
olled
CS

U.S.

Level 4

control=
180,202
Europe

SR
Level 1
2 CS

CVD events
measured by ICD9 codes on health
insurance claims

IV= estrogen plus
CC or SC MP4
DV= incidence &
prevalence of EC

studies
comparing
oral vs.
TD
estrogen
+/progestin
or P4 vs.
non-user

TD E+MP4: no change
(RR 0.93, 95% CI 0.65–
1.33)

TD E2 vs.
oral
estrogen
(type not
specified)
Doses not
available

TD E2 vs oral ET

N/A

TD E+P: ↑VTE risk (RR
2.42, 95% CI 1.84–3.18)

Transdermal estrogen+MP4 is
a safer option for menopausal
women at risk for VTE. May
improve risk/benefit ratio of
HT for all PM women.
Increased VTE risk associated
with progestogens is not a
class effect.

CVD complications:
(adjusted IRR 0.81; 95%
CI, 0.67-0.99).
VTE (adjusted IRR 0.42;
95% CI, 0.19-0.96)

Study #1: HR 2.42; 95%
CI 1.53–3.83 for ever use
of MP4 vs. never use
(SC/CC not specified)
Study #2: HR 1.80; 95%
CI 1.38–2.34 for ever use
of CC with MP4

Findings suggest that
unopposed TD E2 is safer
from a CVD risk standpoint
when compared to unopposed
oral estrogens, but no
conclusions can be drawn
regarding the safety profiles of
bioidentical vs. synthetic oral
ET.

Increased risk of EC among
MP4 users. EC risk higher if
MP4 used for ≥5 years
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HR 1.39; 95% CI 0.99–
1.97 for ≤5 years of CC
with MP4
HR 2.66; 95% CI 1.87–
3.77 for >5 years of CC
with MP4
Stute, P., Wildt, L., & Neulen,
J. (2018). The impact of
micronized progesterone on
breast cancer risk: A
systematic
review. Climacteric, 21(2),
111–122.
https://doi.org/10.1080/13697
137.2017.1421925

Determine the
impact of
estrogen + MP4
on BC risk

N=varies

SR

Peri- and
PM ♀
(mostly in
their 50s)

Level 1

DV=BC measured
by core needle
biopsy or
lumpectomy
Medical records,
self-administered
questionnaire, inperson interviews,
or scheduled visits
at 2 month or 12month intervals

U.S. and
Europe

Mean duration of
HT 2.8 years to
≥10 years
Stute, P., Neulen, J., & Wildt,
L. (2016). The impact of
micronized progesterone on
the endometrium: A
systematic review.
Climacteric, 19(4), 316-328.
https://doi.org/10.1080/13697
137.2016.1187123

Determine if
EPT with MP4
provides
adequate
endometrial
protection

N=varies

SR

Peri- and
PM ♀

Level 1
(40
studies)

IV=EPT w/ MP4
(oral, TD, or
vaginal) for
minimum of 3
months
DV=Endometrial
hyperplasia & EC

E+MP4;
variety of
regimens,
routes
(mostly
oral) and
doses not
always
specified
Compared
synthetic,
bioidentic
al,
placebo,
and/or
non-users
N/A

No ↑BC risk w/ E+ oral or
vaginal MP4 use for ≤5
years
Limited evidence suggests
slight but significant ↑BC
risk w/ E+MP4 >5 years

Practice recommendations: (1)
E+MP4 (oral or vaginal) does
not increase breast cancer risk
if used for ≤5 years. Limited
evidence suggests that BC risk
increases after 5 years E+ oral
MP.

Adherence high in two
studies but not reported in
others

Oral MP4: adequate
endometrial protection if
sequential 200mg/day for
12-14 day/month for up to
5 years
Vaginal MP4: may provide
endometrial protection if
sequential for ≥10 days/
month at 4% (45 mg/day)
or every other day at 100

Detailed expert panel
recommendations to guide
clinical practice
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mg/day for up to 3–5 years
(off-label use)
TD MP4 does not provide
endometrial protection
Tempfer, C. B., Hilal, Z.,
Kern, P., Juhasz-Boess, I., &
Rezniczek, G. A. (2020).
Menopausal hormone therapy
and risk of endometrial
cancer: A systematic
review. Cancers, 12(8), 1-18.
https://doi.org/10.3390/cancer
s12082195

Evaluate EC
risk in ♀ related
to type and
regimen of
progestogen

n=902 PM
♀ w/ EC,
control=
180,202

SR
(2 CS)
Level 1

Europe

IV= estrogen plus
CC or SC MP4

N/A

DV= incidence &
prevalence of EC

Study #1: HR 2.42; 95%
CI 1.53–3.83 for ever use
of MP4 vs. never use
(SC/CC not specified)

Increased risk of EC among
MP4 users. Short term use
(≤5 years) of MP4
recommended

Study #2: HR 1.80; 95%
CI 1.38–2.34 for ever use
of CC with MP4
HR 1.39; 95% CI 0.99–
1.97 for ≤5 years of CC
with MP4
HR 2.66; 95% CI 1.87–
3.77 for >5 years of CC
with MP4

Yang, Z., Hu, Y., Zhang, J.,
Xu, L., Zeng, R., & Kang, D.
(2017). Estradiol therapy and
breast cancer risk in
perimenopausal and
postmenopausal women: A
systematic review and metaanalysis. Gynecological
Endocrinology, (2), 87–92.
https://doi.org/10.1080/09513
590.2016.1248932

Evaluate impact
of estradiol with
and without
progestogen on
BC risk

N=14,475
peri- and
PM ♀
Mostly
Europe

SR &
MA
Level 1
14
studies

IV=Estradiol
therapy +/progestogen,
duration of
exposure, type of
regimen (CC/SC)
DV=BC incidence

TD or oral
E2V or
17-beta
estradiol +
MP4 or P

OR (95% CI):
E2V/E2 only
All studies 1.11 (0.98-1.27)
RCT only 0.90 (0.40-2.02)
EPT w/ progestogen:
MP4 1.00 (0.83-1.20)
MPA 1.19 (1.07-1.33)
NETA 1.44 (1.26-1.65)

No increased risk of BC with
EV and 17-beta estradiol.
Statistically significant ↑in BC
risk with EPT including
synthetic P (MPA, NETA,
LNG). No ↑BC risk with EPT
containing MP4.
↑BC risk with EPT <5 years
(MA included bioidentical
estradiol but combined all
progestogens). Use of EPT >5
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LNG 1.47 (1.17-1.85)

years increases BC risk even
further.

EPT <5yrs 1.39 (1.09-1.78)
EPT >5yrs 2.25 (1.82-2.80)
EPT SC 1.76 (1.28-2.42)

Statistically significant ↑ BC
risk with SC and CC EPT,
however higher risk with CC.

EPT CC 2.90 (1.82-4.61)
Zeng, Z., Jiang, X., Li, X.,
Wells, A., Luo, Y., &
Neapolitan, R. (2018).
Conjugated equine estrogen
and medroxyprogesterone
acetate are associated with
decreased risk of breast cancer
relative to bioidentical
hormone therapy and
controls. PloS One, 13(5), 112. https://doi.org/10.1371/
journal.pone.0197064

Determine BC
risk associated
with different
synthetic and
bioidentical HT
protocols

n=12,404
♀ initiated
HT after
age 50
control=
27,642 ♀
w/ no HT
use after
age 50
U.S.

Retrosp
ective
Level 4

DV=BC diagnosis
ICD-9 codes from
Northwestern
Medicine Medical
Data Warehouse
Mean follow up
time 15.4 years
(HT use) and 17.8
years (controls)

ET +/- P
or MP4
(oral)

BC risk (95% CI):

Drug
doses not
known

Oral E2 (HR 0.65)

CEE (HR 0.31)

CEE+MPA (HR 0.43)
E2+MP4 (HR 1.05)

CEE and CEE+MPA had the
lowest risk of BC.
Oral E2 was associated with
↓BC risk but inferior to CEE.
CEE+MPA findings differed
from WHI
Need additional studies to
substantiate results

AA, African American; BC, breast cancer; BP, blood pressure; CC, continuous combined; CCS, case control study; CEE, conjugated equine estrogens; CI, confidence interval; CID, clinically important
differences; CIMT, carotid artery intima-media thickness; CMA, chlormadinone acetate; CRP, C reactive protein; CS, cohort study; CV, cardiovascular; D, dydrogesterone; DBPC, double blind placebo-controlled;
DV, dependent variable; E, estrogen; E2, estradiol; E2V, estradiol valerate; EPT, estrogen-progesterone therapy; ET, estrogen therapy; EV, estradiol valerate; HR, hazard ratio; HT, hormone therapy; ICD-9,
International Classification of Diseases, Ninth Revision; IRR, Incidence Rate Ratio; IS, ischemic stroke; IV, independent variable; LNG, levonorgestrel; MA, meta-analysis; MP4, micronized progesterone; MPA,
medroxyprogesterone acetate; MDTS, meter-dose transdermal spray; NETA, norethisterone acetate; OR, odds ratio; P, synthetic progestin; PBCCS, population based case control study; PM, post-menopause;
PROLMRDS, partly randomized open-label, multiple-rising-dose study; RCT, randomized control trial; RR, relative risk; SC, sequential combined; SR, systematic review; TG, triglycerides

